Cardiff Oncology Inc (NASDAQ: CRDF) is 175.00% higher on its value in year-to-date trading and has touched a low of $1.41 and a high of $6.42 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The CRDF stock was last observed hovering at around $4.26 in the last trading session, with the day’s loss setting it -0.19%.
Currently trading at $4.07, the stock is 23.02% and 30.80% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.43 million and changing -4.46% at the moment leaves the stock 27.15% off its SMA200. CRDF registered 175.00% gain for a year compared to 6-month gain of 80.09%. The firm has a 50-day simple moving average (SMA 50) of $3.083 and a 200-day simple moving average (SMA200) of $3.20135.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 62.80% loss in the last 1 month and extending the period to 3 months gives it a 55.34%, and is 0.99% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 18.63% over the week and 12.28% over the month.
Cardiff Oncology Inc (CRDF) has around 32 employees, a market worth around $270.73M and $0.69M in sales. Profit margin for the company is -6241.65%. Distance from 52-week low is 188.65% and -36.60% from its 52-week high. The company has generated returns on investments over the last 12 months (-85.38%).
with sales reaching $73k over the same period.The EPS is expected to shrink by -6.21% this year, but quarterly earnings will post 21.48% year-over-year. Quarterly sales are estimated to shrink -53.21% in year-over-year returns.
Cardiff Oncology Inc (CRDF) Top Institutional Holders
110.0 institutions hold shares in Cardiff Oncology Inc (CRDF), with institutional investors hold 29.30% of the company’s shares. The shares outstanding are 66.52M, and float is at 61.34M with Short Float at 13.33%. Institutions hold 27.66% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 2.63 million shares valued at $5.84 million. The investor’s holdings represent 5.883% of the CRDF Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 2.14 million shares valued at $4.74 million to account for 4.7816 of the shares outstanding. The other top investors are ASSENAGON ASSET MANAGEMENT S.A. which holds 1.22 million shares representing 2.7215% and valued at over $2.7 million, while GEODE CAPITAL MANAGEMENT, LLC holds 2.0383 of the shares totaling 0.91 million with a market value of $2.02 million.
Cardiff Oncology Inc (CRDF) Insider Activity
The most recent transaction is an insider purchase by Levine James E., the company’s Chief Financial Officer. SEC filings show that Levine James E. bought 2,752 shares of the company’s common stock on Dec 17 ’24 at a price of $5.42 per share for a total of $14905.0. Following the purchase, the insider now owns 65316.0 shares.
Cardiff Oncology Inc disclosed in a document filed with the SEC on Dec 18 ’24 that Levine James E. (Chief Financial Officer) bought a total of 2,400 shares of the company’s common stock. The trade occurred on Dec 18 ’24 and was made at $5.00 per share for $12000.0. Following the transaction, the insider now directly holds 67716.0 shares of the CRDF stock.
Still, SEC filings show that on Dec 16 ’24, Levine James E. (Chief Financial Officer) acquired 2,564 shares at an average price of $3.83 for $9820.0. The insider now directly holds 62,564 shares of Cardiff Oncology Inc (CRDF).
